奈玛特韦/利托那韦治疗6岁及以上儿童COVID-19研究
这项正在进行的2/3期干预性开放标签研究评估了奈玛特韦/利托那韦在具有重症风险的轻至中度COVID-19儿科参与者中的药代动力学与安全性。报告了至少6岁参与者的数据:75名参与者接受至少一剂,模拟暴露显示超过90%参与者达到有效浓度阈值,药物安全耐受且观察到SARS-CoV-2 RNA显著下降。
要点
- 奈玛特韦/利托那韦在≥6岁、体重≥40kg(300/100mg BID)或20-<40kg(150/100mg BID)儿童中暴露与成人相似。
- 最常见不良事件为腹泻和头痛(各4%),无因治疗相关不良事件停药,无治疗相关严重不良事件。
- 未报告COVID-19相关住院或全因死亡,观察到SARS-CoV-2 RNA从基线至治疗结束显著下降。
核心结论
- 在≥6岁儿科参与者中,奈玛特韦/利托那韦300/100mg BID(体重≥40kg)和150/100mg BID(体重20-<40kg)方案达到与成人相似的暴露,安全且具有抗病毒效果。
研究设计与样本
- 正在进行的2/3期干预性开放标签研究,评估奈玛特韦/利托那韦在具有重症风险的轻至中度COVID-19儿科参与者中的药代动力学和安全性。
- 报告了至少6岁参与者的数据,共75名参与者接受至少一剂奈玛特韦/利托那韦,口服每日两次,持续5天。
- 第1天和第5天稀疏药代动力学样本纳入先前开发的人群药代动力学模型以模拟暴露。
- 疗效通过将儿科暴露与COVID-19感染成人暴露匹配后从成人外推。
- 评估至第34天的安全性和支持性疗效终点(住院/死亡、SARS-CoV-2 RNA浓度随时间变化)。
主要发现
- 模拟暴露显示,队列1(300/100mg BID)和队列2(150/100mg BID)中超过90%的参与者在第1剂后和稳态时达到最低奈玛特韦浓度高于90%有效浓度。
- 奈玛特韦/利托那韦安全且耐受性良好,最常见不良事件为腹泻和头痛(各3名参与者[4%])。
- 无因治疗相关不良事件导致的停药,未报告治疗相关严重不良事件。
- 未报告COVID-19相关住院或全因死亡。
- 观察到SARS-CoV-2 RNA从基线至治疗结束的显著下降。
关键数值与推荐
- 奈玛特韦/利托那韦300/100mg BID用于体重≥40kg的≥6岁参与者,150/100mg BID用于体重20-<40kg的≥6岁参与者,口服每日两次,持续5天。
- 模拟暴露显示超过90%的参与者达到最低奈玛特韦浓度高于90%有效浓度。
- 最常见不良事件为腹泻和头痛,各发生在3名参与者(4%)中。
临床怎么用
- 对于≥6岁、体重≥40kg的具有重症风险的轻至中度COVID-19儿科患者,可考虑奈玛特韦/利托那韦300/100mg BID口服5天。
- 对于≥6岁、体重20-<40kg的具有重症风险的轻至中度COVID-19儿科患者,可考虑奈玛特韦/利托那韦150/100mg BID口服5天。
- 治疗期间需关注腹泻和头痛等不良事件,但研究中未出现因治疗相关不良事件停药或治疗相关严重不良事件。
局限性
- 研究为开放标签设计,非随机对照,支持性疗效终点需谨慎解读。
- 疗效主要通过从成人外推,而非直接在儿科人群中验证。
- 样本量较小(75名参与者),且报告数据仅限至少6岁参与者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: This ongoing phase 2/3 interventional, open-label study evaluated nirmatrelvir/ritonavir (NMV/r) in pediatric participants with mild-to-moderate COVID-19 at risk for severe disease (due to underlying medical conditions). Primary objectives were pharmacokinetics (PK) and safety. We report data from participants aged at least 6 years. METHODS: Twice daily (BID) oral NMV/r was administered for 5 days to participants aged at least 6 years weighing at least 40 kg (Cohort 1) or 20 to <40 kg (Cohort 2). Day 1 and 5 sparse PK samples were incorporated into a previously developed population PK model to simulate exposure. Efficacy was extrapolated from adults by matching pediatric exposure to that in COVID-19-infected adults. Safety through Day 34 and supportive efficacy endpoints (hospitalization/death, SARS-CoV-2 RNA concentration over time) were evaluated. RESULTS: Overall, 75 participants received at least 1 dose. Simulated exposure of NMV/r 300/100 mg BID for Cohort 1 and 150/100 mg BID for Cohort 2 indicated more than 90% of participants achieved minimum NMV concentrations above the 90% effective concentration after dose 1 and at steady state. NMV/r was safe and well tolerated. The most frequently reported adverse events (AEs) were diarrhea and headache (n = 3 [4%] participants each). No discontinuations because of treatment-related AEs occurred. No treatment-related serious AEs were reported. No COVID-19-related hospitalizations or all-cause deaths were reported. Robust reductions in SARS-CoV-2 RNA from baseline to the end of treatment were observed. CONCLUSIONS: In pediatric participants aged at least 6 years, NMV/r 300/100 mg BID (weighing ≥40 kg) and 150/100 mg BID (weighing 20-<40 kg) regimens achieved exposures similar to adults that were safe and had an antiviral effect.
引用
- Gerhart J, Leister-Tebbe H, Chan PLS, et al. Nirmatrelvir/Ritonavir for the Treatment of COVID-19 in Children Aged 6 Years and Older. Pediatrics. 2026. PMID: 42342255. doi:10.1542/peds.2025-073999
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。